that was my initial thoughts as well when the US election results came out.....big pharma would spend more on marketing
having said that, perhaps the vaccine business will be impacted (I mean its not just brain worm anti-vaxxer that is a conspiracy theorists), but the country is addicted to a whole range of drugs, and with less regulation, less oversight and companies given free reign to do whatever they want, it seems to me that the other part of the pharma business will pick up......question is whether MDR will pick up any of that marketing budget
the australian business is seemingly very steady, strong and profitable, but even with expansion of services, they are unlikely to be able to make much more without raising the monthly rates for pharmacies......I think they should, but it probably needs to happen in a slow, steady way that will not resultin any major chain jumping off
What is reassuring (although not sure how they can back this up without confirmed contracts in 2H) is they indicate FY25 positive EBITDA.....but importantly did not indicate growth on FY24 which may be dissapointing
Add to My Watchlist
What is My Watchlist?
